as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 25 Sep 2026
₹673.75
Change
-3.4 (-0.5%)
Open
₹684.0
Prev. Close
₹677.15
Day High
₹697.75
Day Low
₹636.8
Volume Analysis
Traded
41,244
Delivered
23,402
Delivery %
56.74%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (2)
- •Promoter holding is rising
- •Strong operating margin (31.0%)
Weaknesses (0)
No signal for this stock
Opportunities (2)
- •Strong 3-year EPS growth (22.0%)
- •Strong 3-year revenue growth (30.5%)
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹763.01 | ₹730.38 | ₹702.06 | ₹669.43 | ₹641.11 | ₹608.48 | ₹580.16 |
| Fibonacci | ₹730.38 | ₹707.1 | ₹692.71 | ₹669.43 | ₹646.15 | ₹631.76 | ₹608.48 |
| Camarilla | ₹690.51 | ₹684.92 | ₹679.34 | ₹669.43 | ₹668.16 | ₹662.58 | ₹656.99 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
—
1 Week
-6.52%
1 Month
+24.17%
3 Months
—
6 Months
—
1 Year
—
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹198.79
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
10.08%
Net margin 15.15% × asset turnover 0.52x × equity multiplier 1.28x
Company Overview
Sector
Healthcare
Market Cap
₹946 Cr
P/E (TTM)
61.2
ROE
10.8%
Book Value
₹127.0
Face Value
₹10.0
Source: Screener.in (Consolidated figures) — data as of 23 Sep 2026. Not investment advice.
TopFund Analysis
Shree Ganesh Remedies Ltd holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 69/100. The strongest factor is Financial Strength (100/100), while Valuation (13/100) is the weakest area to weigh before deciding. Notably: Promoter holding is rising; strong operating margin (31.0%). Strong 3-year EPS growth (22.0%).
TopFund Score — Fundamentals Quality
69/100 — GoodData confidence: 77/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 27 Sep 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Liquidity
From Screener.in
- −Though the company is reporting repeated profits, it is not paying out dividend
- −Debtor days have increased from 80.8 to 109 days.
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Shree Ganesh Remedies held its 31st AGM on September 12, 2026; approved financials and independent director appointment.
Newspaper Publication for Notice of Annual General Meeting
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Jun 2021 | Sep 2021 | Dec 2021 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 13 | 17 | 21 | 37 | 25 | 32 | 27 | 24 | 25 | 30 | 21 | 33 | 14 |
| Expenses + | 10 | 13 | 15 | 20 | 17 | 21 | 17 | 15 | 17 | 21 | 14 | 22 | 11 |
| Operating Profit | 3 | 4 | 6 | 17 | 8 | 11 | 10 | 10 | 7 | 10 | 7 | 11 | 3 |
| OPM % | 24.15% | 26.22% | 27.31% | 45.38% | 32.81% | 34.98% | 36.64% | 40.44% | 29.59% | 31.73% | 31.88% | 34.28% | 23.33% |
| Other Income + | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 2 | 1 | 1 | 1 | 1 | 1 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0 |
| Depreciation | 1 | 1 | 1 | 2 | 2 | 2 | 3 | 2 | 2 | 3 | 3 | 3 | 2 |
| Profit before tax | 3 | 4 | 6 | 16 | 6 | 9 | 8 | 9 | 5 | 7 | 4 | 9 | 2 |
| Tax % | 28.75% | 22.76% | 25.4% | 22.46% | 26.7% | 25.81% | 27.89% | 24.83% | 25.0% | 26.23% | 22.36% | 28.21% | 27.45% |
| Net Profit + | 2 | 3 | 4 | 13 | 5 | 6 | 5 | 7 | 3 | 5 | 3 | 6 | 1 |
| EPS in Rs | 2 | 2 | 3 | 10 | 4 | 5 | 4 | 5 | 3 | 4 | 2 | 5 | 1 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|
| Sales + | 35 | 64 | 49 | 126 | 109 | 109 | 99 |
| Expenses + | 26 | 52 | 35 | 84 | 69 | 74 | 68 |
| Operating Profit | 9 | 13 | 14 | 42 | 39 | 35 | 31 |
| OPM % | 25.0% | 20.0% | 28.0% | 33.0% | 36.0% | 32.0% | 31.0% |
| Other Income + | 1 | 4 | 2 | 3 | 4 | 3 | 3 |
| Interest | 0 | 1 | 0 | 1 | 2 | 4 | 3 |
| Depreciation | 1 | 2 | 3 | 6 | 10 | 10 | 10 |
| Profit before tax | 9 | 14 | 13 | 38 | 31 | 24 | 21 |
| Tax % | 28.0% | 23.0% | 25.0% | 26.0% | 26.0% | 26.0% | — |
| Net Profit + | 6 | 10 | 10 | 28 | 23 | 18 | 15 |
| EPS in Rs | 5 | 8 | 8 | 22 | 18 | 14 | 12 |
| Dividend Payout % | 18.0% | 13.0% | 18.0% | 2.0% | 0.0% | 0.0% | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Reserves | 25 | 33 | — | 109 | 132 | 150 |
| Borrowings + | 1 | 4 | — | 36 | 38 | 31 |
| Other Liabilities + | 7 | 9 | — | 12 | 8 | 14 |
| Total Liabilities | 41 | 55 | — | 171 | 192 | 208 |
| Fixed Assets + | 14 | 20 | — | 81 | 95 | 105 |
| CWIP | 0 | 0 | — | 17 | 9 | 13 |
| Investments | 4 | 3 | — | 5 | 18 | 13 |
| Other Assets + | 23 | 32 | — | 69 | 70 | 78 |
| Total Assets | 41 | 55 | — | 171 | 192 | 208 |
| Equity Capital | 9 | 9 | — | 13 | 13 | 13 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Cash from Operating Activity + | -5 | 5 | 3 | 30 | 31 | 24 |
| Cash from Investing Activity + | 0 | -3 | -1 | -33 | -35 | -9 |
| Cash from Financing Activity + | 0 | 0 | -1 | 10 | -1 | -12 |
| Net Cash Flow | -5 | 1 | 2 | 7 | -6 | 3 |
| CFO/OP | -60 | 37 | 24 | 92 | 104 | 82 |
| Free Cash Flow | -5 | 5 | 3 | -1 | 7 | 7 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 30.67% | 30.66% | 30.67% | 30.66% | 29.5% | 27.19% | 27.2% | 27.2% | 27.19% | 27.2% | 27.16% | 26.65% |
| Promoters | 69.33% | 69.33% | 69.33% | 69.33% | 70.49% | 72.8% | 72.8% | 72.8% | 72.8% | 72.8% | 72.83% | 72.83% |
| FII | 0.0% | 0.0% | 0.0% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.0% | 0.0% | 0.0% |
| DII | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.52% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Shree Ganesh Remedies Ltd (this stock) | 946 | 61.2 | 5.8 | 10.8% |
| Health X Platform Limited | 908 | 510.0 | 1.42 | 0.29% |
| Bafna Pharmaceuticals Ltd | 842 | — | 1.65 | -6.18% |
| Gaudium Ivf N Women H L | 837 | 36.2 | 5.55 | 24.7% |
| Themis Medicare Ltd. | 1,077 | 624.0 | 2.7 | 0.41% |
| Bharat Parenterals Ltd. | 1,077 | — | 3.3 | -2.54% |
| Laxmi Dental Limited | 1,097 | 31.6 | 4.49 | 14.8% |
Which Mutual Funds Hold Shree Ganesh Remedies Ltd?
Frequently Asked Questions about Shree Ganesh Remedies Ltd
Shree Ganesh Remedies Ltd (SGRL) closed at ₹673.75 on NSE on 25 September 2026, down 3.4 (0.5%) from the previous close.
Shree Ganesh Remedies Ltd trades on the NSE (National Stock Exchange of India) under the symbol SGRL.
Shree Ganesh Remedies Ltd has a trailing twelve-month P/E (price-to-earnings) ratio of 61.2.
Shree Ganesh Remedies Ltd has a dividend yield of 0.0%.
Shree Ganesh Remedies Ltd's 52-week high is ₹759.0 and its 52-week low is ₹381.0.
Shree Ganesh Remedies Ltd has a market capitalisation of ₹946 crore.
Shree Ganesh Remedies Ltd has a TopFund Quality Score of 69/100 (Good), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Shree Ganesh Remedies Ltd?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.